Effect of IDH mutation on survival prognosis in patients with high-level meningioma

Meningia tumor is a common central nervous system tumor with an annual incidence rate of 8.3 per 100,000, of which 80%-90% of meningioma is a low-grade brain tumor with a recurrence rate of 7%-20%Recurrence and mortality rates of high-level meningioma scored higher; 5%-15% meningioma was WHO level II, with a recurrence rate of 30%-40%, and the remaining 1%-3% was WHO III, with a recurrence rate of 50%-80%Corey MGill of the Icahn School of Medicine in New York, USA, reviewed the high-level meningia tumor's isocitrate dehydrogenase (ISocitrate dehydrogenase, IDH) mutation and its impact on patient survival, published online March 2020research methods
this is the first study to report the occurrence of IDH mutations in high-level meningiomas (WHO levels II and III)The authors used new-generation sequencing techniques to sequence genetic exon sons in 134 patients with high-level meningioma, and found that only 3 (2.2%) patients had IDH1 or IDH2 mutationsthe results of the studythe authors of 3 patients of clinical data and mutation results to highlight:cases of female patients aged 1:53 years old, preoperative CT scan showed that the tumor is located in the left frontal precranial bed, the size of 4.1 x 3.6 x 4.1 cm, the tumor is partially calcifiedPostoperative pathology test results suggested that primary atypical atypical meningioma (WHO grade II), accompanied by epithelial antigen (EMA) and progesterone receptor (PR) positive, and invasion of surrounding brain tissueGene sequencing is IDH 1pArg 132His mutation (10.5%, 334x)The patient has survived for 10.1 yearscases of 2:37-year-old female patients, preoperative MRI imaging showed that the tumor is located in the left forehead, the size of about 5.4 x 7.5 x 6.9 cmThe results of postoperative pathology indicate that the recurrent WHO Grade III inter-variant meningioma invades the surrounding brain tissueGene sequencing results were IDH1 p.Arg132Gly mutations (6.9%, 2000x) The patient has survived for 13.3 years 3:67-year-old female patient with a tumor on the top convex surface The pathological test results were recurrent WHO-grade atypical meningiomas, accompanied by partial necrosis and EMA positive The genetic sequencing result was the IDH2p.Arg140Gln mutation (5.0%, 2000x) The patient survived 10.9 years after surgery Conclusion
in summary, 3 patients with high-level meningioma with IDH1/2 mutation had a survival span of more than 10 years after surgical excision The authors believe that clinically, the idh1/2 mutation in high-level meningioma should be screened by exosome sequencing, which can benefit patients in clinical trials currently used in IDH inhibitors Further research in the future should confirm that the IDH1/2 mutation state affects the survival prognosis of patients with high-level meningioma Copyright Notice the copyright of works published by Outside Information APP, including but not limited to text, pictures, videos, are owned by the sponsor/original author and of the God's Information , and no one may steal any content directly or indirectly by means of adaptation, cutting, reproduction, reproduction, recording, etc without the express authorization of the outside information Works authorized by the Outside Information shall be used within the scope of authorization, please indicate the source: the of the Outside Information If there is a violation, outside the information will reserve the right to further pursue the legal liability of the infringer outside the information welcome individuals to forward and share the works published by this number.